EP 1608662 A1 20051228 - GUANIDINE DERIVATIVES AND USE THEREOF AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS
Title (en)
GUANIDINE DERIVATIVES AND USE THEREOF AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS
Title (de)
GUANIDINDERIVATE UND IHRE VERWENDUNG ALS NEUROPEPTID FF REZEPTOR-ANTAGONISTEN
Title (fr)
DERIVES DE GUANIDINE ET LEUR UTILISATION COMME ANTAGONISTES DES RECEPTEURS DU NEUROPEPTIDE FF
Publication
Application
Priority
- CH 2004000175 W 20040322
- CH 4662003 A 20030320
Abstract (en)
[origin: WO2004083218A1] The invention relates to guanidine derivatives of formula (I) where: A = a chain of 3-c6 carbon atoms, one of which can be replaced by -N(R')- or -O- and R' = H or a substituent, where the ring skeleton only contains both double bonds of the thiazole component, the pharmaceutically-acceptable acid addition salts of basic compounds of formula (I), the pharmaceutically-acceptable salts of compounds of formula (I),, comprising acid groups, with bases, the pharmaceutically-acceptable esters of hydroxy or carboxyl group containing compounds of formula (I) and the solvates or hydrates thereof, which are partly known and partly novel and exhibit a neuropeptide FF receptor antagonist effect. The above are suitable for the treatment of pain and hyperalgesia, withdrawal symptoms in alcohol, psychotropic and nicotine dependencies, for improvement or cure of said dependencies, for regulation of insulin excretion, food intake, memory functions, blood pressure, electrolyte and energy management and for treatment of urinary incontinence. The above can be produced using generally used methods and processed to give medicaments.
IPC 1-7
C07D 513/04; C07D 277/82; C07D 277/60; C07D 417/04; A61K 31/428; A61K 31/429; A61K 31/437
IPC 8 full level
A61K 31/428 (2006.01); A61K 31/429 (2006.01); A61K 31/437 (2006.01); C07D 277/60 (2006.01); C07D 277/82 (2006.01); C07D 417/04 (2006.01); C07D 513/04 (2006.01)
CPC (source: EP KR US)
A61K 31/428 (2013.01 - EP KR US); A61K 31/429 (2013.01 - EP US); A61K 31/437 (2013.01 - EP US); A61P 3/00 (2018.01 - EP); A61P 3/10 (2018.01 - EP); A61P 5/50 (2018.01 - EP); A61P 9/12 (2018.01 - EP); A61P 13/02 (2018.01 - EP); A61P 25/04 (2018.01 - EP); A61P 25/28 (2018.01 - EP); A61P 25/30 (2018.01 - EP); A61P 25/32 (2018.01 - EP); A61P 25/34 (2018.01 - EP); A61P 25/36 (2018.01 - EP); A61P 29/00 (2018.01 - EP); A61P 43/00 (2018.01 - EP); C07D 277/60 (2013.01 - EP US); C07D 277/82 (2013.01 - EP US); C07D 417/04 (2013.01 - EP US); C07D 513/04 (2013.01 - EP KR US)
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR
DOCDB simple family (publication)
WO 2004083218 A1 20040930; AR 043662 A1 20050803; AU 2004222224 A1 20040930; BR PI0408357 A 20060321; CA 2518679 A1 20040930; CL 2004000553 A1 20050204; CN 100355758 C 20071219; CN 1761673 A 20060419; EP 1608662 A1 20051228; JP 2006520330 A 20060907; KR 20050107611 A 20051114; MX PA05009855 A 20051206; NO 20054743 L 20051014; RU 2005132308 A 20060320; RU 2337911 C2 20081110; TW 200510434 A 20050316; US 2006194788 A1 20060831; US 7727979 B2 20100601
DOCDB simple family (application)
CH 2004000175 W 20040322; AR P040100923 A 20040319; AU 2004222224 A 20040322; BR PI0408357 A 20040322; CA 2518679 A 20040322; CL 2004000553 A 20040317; CN 200480007447 A 20040322; EP 04722212 A 20040322; JP 2006504158 A 20040322; KR 20057016769 A 20050908; MX PA05009855 A 20040322; NO 20054743 A 20051014; RU 2005132308 A 20040322; TW 93107426 A 20040319; US 54968505 A 20050919